Alpha Cognition Inc. Common Stock(ACOG)Earnings, Financials & Key RatiosAlpha Cognition Inc. Common Stock (ACOG) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current operating cash flow deficit of $11.8M and the rapid decline in cash from $66.1M in 2025Q4 suggest that the firm faces significant liquidity pressure that may require further dilutive capital raises.
Alpha Cognition Inc. Common Stock (ACOG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Alpha Cognition Inc. Common Stock (ACOG) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.37vs $0.41+9.8% | $4Mvs $3M+3.2% |
| Q2 2026 | Mar 26, 2026 | $0.30vs $0.27-11.1% | $3Mvs $3M-12.5% |
| Q4 2025 | Nov 13, 2025 | $0.30vs $0.43+30.2% | $3Mvs $5M-46.0% |
| Q3 2025 | Aug 14, 2025 | $0.65vs $0.46-41.3% | $2Mvs $4M-60.1% |
Recent stock market news and headlines for Alpha Cognition Inc. Common Stock (ACOG)
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. “On behalf of the entire Board of Directors, we are.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a mult.
Key metrics vs top competitors for Alpha Cognition Inc. Common Stock (ACOG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.81 | $105.77M | -5.82 | — | -202.24% | -39.75% | — | |
| $2.60 | $240.95M | -4.81 | — | — | -38.76% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $350.06 | $10.11B | -25.97 | -100% | — | -43.02% | — | |
| $2.66 | $270.72M | -3.07 | -86.92% | -1971.7% | -101.76% | — | |
| $216.63 | $31.98B | 24.53 | 1.39% | 13.92% | 7.55% | — |
Alpha Cognition Inc. Common Stock (ACOG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Alpha Cognition Inc. Common Stock (ACOG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 20, 2026·SEC
Apr 14, 2026·SEC
Mar 27, 2026·SEC
Get notified when ACOG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alpha Cognition Inc. Common Stock (ACOG) stock FAQ — growth, dividends, profitability & financials explained
Alpha Cognition Inc. Common Stock (ACOG) reported $10.8M in revenue for fiscal year 2025.
Alpha Cognition Inc. Common Stock (ACOG) reported a net loss of $25.1M for fiscal year 2025.
Alpha Cognition Inc. Common Stock (ACOG) has a return on equity (ROE) of -39.8%. Negative ROE indicates the company is unprofitable.
Alpha Cognition Inc. Common Stock (ACOG) had negative free cash flow of $30.4M in fiscal year 2025, likely due to heavy capital investments.
